Kojibiose ameliorates arachidic acid-induced metabolic alterations in hyperglycaemic rats.
Herein we hypothesise the positive effects of kojibiose (KJ), a prebiotic disaccharide, selected for reducing hepatic expression of inflammatory markers in vivo that could modulate the severity of saturated arachidic acid (ARa)-induced liver dysfunction in hyperglycaemic rats. Animals were fed daily (20 d) with ARa (0·3 mg) together or not with KJ (22 mg approximately 0·5 %, w/w diet). Glucose, total TAG and cholesterol contents and the phospholipid profile were determined in serum samples. Liver sections were collected for the expression (mRNA) of enzymes and innate biomarkers, and intrahepatic macrophage and T-cell populations were analysed by flow cytometry. ARa administration increased the proportion of liver to body weight that was associated with an increased (by 11 %) intrahepatic macrophage population. These effects were ameliorated when feeding with KJ, which also normalised the plasmatic levels of TAG and N-acyl-phosphatidylethenolamine in response to tissue damage. These results indicate that daily supplementation of KJ significantly improves the severity of ARa-induced hepatic alterations.
1Instituto Universitario de Ingeniería de Alimentos para el Desarrollo (IIAD),Universidad Politécnica de Valencia,Valencia 46022,Spain.
José
J
Moisés Laparra
2Instituto de Investigación en Ciencias de la Alimentación,CIAL (CSIC-UAM),CEI (UAM+CSIC),Madrid 28049,Spain.
Marina
M
Díez-Municio
2Instituto de Investigación en Ciencias de la Alimentación,CIAL (CSIC-UAM),CEI (UAM+CSIC),Madrid 28049,Spain.
F
F
Javier Moreno
2Instituto de Investigación en Ciencias de la Alimentación,CIAL (CSIC-UAM),CEI (UAM+CSIC),Madrid 28049,Spain.
Miguel
M
Herrero
D000818:Animals; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D004187:Disaccharides / Q000494:pharmacology*; D004195:Disease Models, Animal; D004537:Eicosanoic Acids / Q000009:adverse effects*; D005260:Female; D006943:Hyperglycemia / Q000139:chemically induced / Q000188:drug therapy*; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D008264:Macrophages / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D010743:Phospholipids / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013601:T-Lymphocytes / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D015415:Biomarkers; D001786:Blood Glucose; D004187:Disaccharides; D004537:Eicosanoic Acids; D010743:Phospholipids; D014280:Triglycerides; D002784:Cholesterol; C008237:kojibiose; C094477:arachidic acid
ANGP4 angiopoietin-like protein 4; ARa arachidic acid; Arachidic acid; Hyperglycaemia; KJ kojibiose; Kojibiose; LPC lysophosphatidylcholine; Liver inflammation; PL phospholipid; STZ streptozotocin; Steatosis; TLR4 toll-like receptor-4